Our Approach
Accelerate regenerative medicine development by leveraging naturally existing genetic pathways in the human trophoblast stem cell
Accelerate regenerative medicine development by leveraging naturally existing genetic pathways in the human trophoblast stem cell
We have 54 granted patents and 46 pending patents globally relating to human trophoblast stem cell. We also have developed proprietary know-how to culture and differentiate the hTSC.
hTSC has robust gene expressions that supports stem cell plasticity and regenerative potential.
Highly expressed genes relating to blood stem cells; potential for immunotherapy
Many genes are highly expressed relating to key organ systems; potential for cell therapy relating to organ repair
hTSC express many genes that are connected to key pathways and functions
Large number of longevity and exosome related genes points to potentials to affect age related diseases
Ensuring our cell therapy products meet the highest standards of Good Manufacturing Practice (GMP) and Chemistry, Manufacturing, and Controls (CMC) is essential to delivering safe and effective therapies.
With Theragent overseeing our GMP & CMC processes, we rigorously control our manufacturing to ensure consistent product quality, while our collaboration with Darkhorse Consulting ensures comprehensive compliance with all regulatory requirements.
Ensuring our cell therapy products meet the highest standards of Good Manufacturing Practice (GMP) and Chemistry, Manufacturing, and Controls (CMC) is essential to delivering safe and effective therapies.
Explore how our starting materials and genetically engineered platforms can help accelerate your regenerative medicine product time to market.
Explore our platforms
Learn about our exciting work with leading biopharma companies and research institutions.
We are ready to share our hTSCs with you to help you accelerate your research and product development.
Partner with Us
